Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Akari Therapeutics

DB:CLAB
Snowflake Description

Moderate growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CLAB
DB
$37M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
  • Akari Therapeutics has significant price volatility in the past 3 months.
CLAB Share Price and Events
7 Day Returns
-24.8%
DB:CLAB
2.8%
DE Pharmaceuticals
-0.6%
DE Market
1 Year Returns
-63%
DB:CLAB
-11.1%
DE Pharmaceuticals
-20.9%
DE Market
CLAB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Akari Therapeutics (CLAB) -24.8% -36% -29.5% -63% - -
DE Pharmaceuticals 2.8% -19.5% -20.8% -11.1% 8.2% -7.5%
DE Market -0.6% -20% -26.3% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • CLAB underperformed the Pharmaceuticals industry which returned -11.1% over the past year.
  • CLAB underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
CLAB
Industry
5yr Volatility vs Market

Value

 Is Akari Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Akari Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Akari Therapeutics.

DB:CLAB Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 4.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:CLAB
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.1%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.686 (1 + (1- 19%) (0%))
0.79
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (0.8 * 6.07%)
4.47%

Discounted Cash Flow Calculation for DB:CLAB using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Akari Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:CLAB DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 4.47%)
2020 -18.20 Analyst x1 -17.42
2021 -13.80 Analyst x1 -12.65
2022 -13.10 Analyst x1 -11.49
2023 -10.20 Analyst x1 -8.56
2024 20.10 Analyst x1 16.16
2025 30.37 Est @ 51.1% 23.37
2026 41.20 Est @ 35.65% 30.34
2027 51.43 Est @ 24.84% 36.26
2028 60.32 Est @ 17.27% 40.71
2029 67.54 Est @ 11.97% 43.63
Present value of next 10 years cash flows $140.00
DB:CLAB DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $67.54 × (1 + -0.39%) ÷ (4.47% – -0.39%)
$1,385.41
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,385.41 ÷ (1 + 4.47%)10
$895.01
DB:CLAB Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $140.00 + $895.01
$1,035.01
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,035.01 / 28.73
$36.03
DB:CLAB Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:CLAB represents 0.79845x of NasdaqCM:AKTX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.79845x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 36.03 x 0.79845
€28.77
Value per share (EUR) From above. €28.77
Current discount Discount to share price of €1.03
= -1 x (€1.03 - €28.77) / €28.77
96.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Akari Therapeutics is available for.
Intrinsic value
>50%
Share price is €1.03 vs Future cash flow value of €28.77
Current Discount Checks
For Akari Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Akari Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Akari Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Akari Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Akari Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CLAB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.93
NasdaqCM:AKTX Share Price ** NasdaqCM (2020-04-03) in USD $1.29
Europe Pharmaceuticals Industry PE Ratio Median Figure of 55 Publicly-Listed Pharmaceuticals Companies 20.47x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Akari Therapeutics.

DB:CLAB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:AKTX Share Price ÷ EPS (both in USD)

= 1.29 ÷ -0.93

-1.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akari Therapeutics is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.
  • Akari Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Akari Therapeutics's expected growth come at a high price?
Raw Data
DB:CLAB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
36.2%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.49x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.18x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Akari Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Akari Therapeutics's assets?
Raw Data
DB:CLAB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-0.08
NasdaqCM:AKTX Share Price * NasdaqCM (2020-04-03) in USD $1.29
Germany Pharmaceuticals Industry PB Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 1.66x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:CLAB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:AKTX Share Price ÷ Book Value per Share (both in USD)

= 1.29 ÷ -0.08

-15.73x

* Primary Listing of Akari Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akari Therapeutics has negative assets, we can't compare the value of its assets to the DE Pharmaceuticals industry average.
X
Value checks
We assess Akari Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Akari Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Akari Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
36.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Akari Therapeutics expected to grow at an attractive rate?
  • Akari Therapeutics's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Akari Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Akari Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:CLAB Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CLAB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 36.2%
Europe Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 13%
Europe Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CLAB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CLAB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 77 29 22 1
2023-12-31 29 -7 -10 1
2022-12-31 18 -6 -12 1
2021-12-31 9 -15 -15 1
2020-12-31 0 -21 -19 2
2020-04-05
DB:CLAB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -13 -17
2019-09-30 -14 -13
2019-06-30 -14 -14
2019-03-31 -18 -18
2018-12-31 -23 -16
2018-09-30 -27 -25
2018-06-30 -30 -32
2018-03-31 -27 -24
2017-12-31 -32 -35
2017-09-30 -30 -32
2017-06-30 -25 -22
2017-03-31 -26 -28

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Akari Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Akari Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CLAB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Akari Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CLAB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.01 0.01 0.01 1.00
2023-12-31 -0.01 -0.01 -0.01 1.00
2022-12-31 -0.01 -0.01 -0.01 1.00
2021-12-31 -0.01 -0.01 -0.01 1.00
2020-12-31 -0.01 -0.01 -0.01 1.00
2020-04-05
DB:CLAB Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.93
2019-09-30 -0.76
2019-06-30 -0.87
2019-03-31 -1.14
2018-12-31 -1.07
2018-09-30 -1.66
2018-06-30 -2.24
2018-03-31 -1.81
2017-12-31 -2.84
2017-09-30 -2.68
2017-06-30 -1.83
2017-03-31 -2.36

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Akari Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Akari Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Akari Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Akari Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Akari Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Akari Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Akari Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Akari Therapeutics's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Akari Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Akari Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CLAB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -17.11 8.22 8.74
2019-09-30 -12.74 8.46 5.40
2019-06-30 -13.77 9.49 6.94
2019-03-31 -17.67 9.91 8.47
2018-12-31 -16.47 10.90 11.80
2018-09-30 -25.07 12.33 16.55
2018-06-30 -31.86 12.11 19.63
2018-03-31 -24.15 12.82 18.29
2017-12-31 -35.40 11.80 23.29
2017-09-30 -31.57 11.29 22.74
2017-06-30 -21.61 11.36 20.15
2017-03-31 -27.74 9.87 21.81
2016-12-31 -18.14 9.94 17.31
2016-09-30 -3.38 9.02 12.67
2016-06-30 -51.72 8.77 10.19
2016-03-31 -46.61 7.00 5.74
2015-12-31 -45.32 5.50 5.80
2015-09-30 -52.90 2.42 4.95
2015-06-30 -4.37 0.49 3.79
2015-03-31 -3.34 0.29 2.98
2014-12-31 -1.95 0.30 1.62
2013-12-31 -1.10 0.14 0.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Akari Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Akari Therapeutics has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Akari Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Akari Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Akari Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Akari Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Akari Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Akari Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Akari Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Akari Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Akari Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Akari Therapeutics Company Filings, last reported 3 months ago.

DB:CLAB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -1.77 0.00 5.73
2019-09-30 3.25 0.00 6.27
2019-06-30 -1.37 0.00 2.74
2019-03-31 1.22 0.00 6.15
2018-12-31 3.11 0.00 5.45
2018-09-30 6.30 0.00 10.07
2018-06-30 8.63 0.00 15.07
2018-03-31 16.32 0.00 23.78
2017-12-31 17.15 0.00 28.11
2017-09-30 13.04 0.00 20.97
2017-06-30 22.85 0.00 30.12
2017-03-31 22.40 0.00 34.94
2016-12-31 34.10 0.00 44.12
2016-09-30 41.04 0.00 50.63
2016-06-30 40.58 0.00 55.78
2016-03-31 46.36 0.00 61.43
2015-12-31 48.72 0.00 68.92
2015-09-30 41.33 3.03 78.77
2015-06-30 -0.77 0.00 0.20
2015-03-31 2.22 0.53 3.33
2014-12-31 2.22 0.53 3.33
2013-12-31 0.29 0.11 0.55
  • Akari Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Akari Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Akari Therapeutics has less than a year of cash runway based on current free cash flow.
  • Akari Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 22.8% each year.
X
Financial health checks
We assess Akari Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Akari Therapeutics has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Akari Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Akari Therapeutics dividends.
If you bought €2,000 of Akari Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Akari Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Akari Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CLAB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 39 Stocks 3.2%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CLAB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Akari Therapeutics has not reported any payouts.
  • Unable to verify if Akari Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Akari Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Akari Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Akari Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Akari Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Akari Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Akari Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Clive Richardson
COMPENSATION $773,966
AGE 54
TENURE AS CEO 1.9 years
CEO Bio

Mr. Clive Richardson serves as the Chief Executive Officer of Akari Therapeutics, Plc since 2019. Mr. Richardson has been the Chief Operations Officer and Director of Akari Therapeutics, Plc since September 16, 2015 and 2015 respectively and served as its Interim Chief Executive Officer since May 8, 2018 until 2019. Mr. Richardson serves as the Head of Operations for Volution. He served as Consultant to Varleigh Immuno Pharmaceuticals since inception in 2008. Prior to working for Volution and Varleigh, he served as a Member of the Board of Directors for a range of international healthcare companies, including CIS Healthcare Ltd. and Clinisys Ltd. He served as the Head of Equities Research for Investec Bank and worked as a Strategy Consultant for L.E.K. Consulting. Mr. Richardson holds an M.A. in Zoology from Trinity College, Oxford University.

CEO Compensation
  • Clive's compensation has increased whilst company is loss making.
  • Clive's remuneration is higher than average for companies of similar size in Germany.
Management Team

Ray Prudo

TITLE
Executive Chairman
COMPENSATION
$318K
AGE
74

Clive Richardson

TITLE
COO, CEO & Director
COMPENSATION
$774K
AGE
54
TENURE
1.9 yrs

Annie Mack

TITLE
Financial Controller

Miles Nunn

TITLE
Chief Scientific Officer
Board of Directors Tenure

Average tenure and age of the Akari Therapeutics board of directors in years:

4.3
Average Tenure
69
Average Age
  • The tenure for the Akari Therapeutics board of directors is about average.
Board of Directors

Clive Richardson

TITLE
COO, CEO & Director
COMPENSATION
$774K
AGE
54
TENURE
5.3 yrs

James Hill

TITLE
Independent Director
COMPENSATION
$76K
AGE
73
TENURE
4.6 yrs

Ray Prudo

TITLE
Executive Chairman
COMPENSATION
$318K
AGE
74
TENURE
4.6 yrs

Don Williams

TITLE
Independent Director
COMPENSATION
$79K
AGE
60
TENURE
3.8 yrs

Peter Feldschreiber

TITLE
Independent Director
COMPENSATION
$85K
AGE
74
TENURE
2.3 yrs

Stuart Ungar

TITLE
Independent Director
COMPENSATION
$65K
AGE
75
TENURE
4.6 yrs

David Byrne

TITLE
Independent Director
COMPENSATION
$65K
AGE
59
TENURE
4 yrs

Michael Grissinger

TITLE
Director
COMPENSATION
$85K
AGE
65
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Akari Therapeutics individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
30. Mar 20 Buy Ray Prudo Individual 19. Feb 20 19. Feb 20 150,000 €1.57 €236,207
X
Management checks
We assess Akari Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Akari Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

Details
Name: Akari Therapeutics, Plc
CLAB
Exchange: DB
Founded:
$34,351,239
28,728,955
Website: http://www.akaritx.com
Address: Akari Therapeutics, Plc
75/76 Wimpole Street,
London,
W1G 9RT,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM AKTX SPONSORED ADR Nasdaq Capital Market US USD 20. Jun 2014
DB CLAB SPONSORED ADR Deutsche Boerse AG DE EUR 20. Jun 2014
Number of employees
Current staff
Staff numbers
13
Akari Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 02:43
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/02
Last earnings filing: 2020/03/31
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.